Solid Biosciences (SLDB) Cash & Equivalents: 2017-2024
Historic Cash & Equivalents for Solid Biosciences (SLDB) over the last 8 years, with Sep 2024 value amounting to $64.4 million.
- Solid Biosciences' Cash & Equivalents rose 31.32% to $64.4 million in Q3 2024 from the same period last year, while for Sep 2024 it was $64.4 million, marking a year-over-year increase of 31.32%. This contributed to the annual value of $74.0 million for FY2023, which is 52.37% down from last year.
- According to the latest figures from Q3 2024, Solid Biosciences' Cash & Equivalents is $64.4 million, which was down 32.82% from $95.9 million recorded in Q2 2024.
- Solid Biosciences' Cash & Equivalents' 5-year high stood at $268.5 million during Q1 2021, with a 5-year trough of $24.8 million in Q3 2020.
- Over the past 3 years, Solid Biosciences' median Cash & Equivalents value was $91.6 million (recorded in 2023), while the average stood at $95.0 million.
- Its Cash & Equivalents has fluctuated over the past 5 years, first slumped by 73.82% in 2020, then skyrocketed by 404.82% in 2021.
- Quarterly analysis of 5 years shows Solid Biosciences' Cash & Equivalents stood at $154.7 million in 2020, then fell by 23.01% to $119.1 million in 2021, then soared by 30.43% to $155.4 million in 2022, then tumbled by 52.37% to $74.0 million in 2023, then skyrocketed by 31.32% to $64.4 million in 2024.
- Its Cash & Equivalents stands at $64.4 million for Q3 2024, versus $95.9 million for Q2 2024 and $117.6 million for Q1 2024.